So Far This Year, Regulus Therapeutics Inc. (RGLS) Reached A New High 3 times

As of Friday close, Regulus Therapeutics Inc.’s (NASDAQ:RGLS) stock was down -$0.03, moving down -12.34 percent to $0.22. The average number of shares traded per day over the past five days has been 14,263,420 shares. 3 times new highs have been achieved over the past 5 days, with a $0.0433 gain in that time frame. In the last twenty days, the average volume was 4,043,240, while in the previous 50 days, it was 2,180,018.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .


Since last month, RGLS stock retreated -18.75%. Shares of the company fell to $0.1576 on 05/09/22, the lowest level in the past month. A 52-week high of $1.48 was reached on 04/04/22 after having rallying from a 52-week low of $0.16. Since the beginning of this year, RGLS’s stock price has dropped by -31.65% or -$0.0997, and marked a new high 3 times. However, the stock has declined by -85.45% since its 52-week high.

Regulus Therapeutics Inc. (RGLS) last reported insider trading activity 99 days ago on Feb 04. Drygin Denis, the Chief Scientific Officer of the company, purchased of 23,314 shares for $0.23 on Feb 04. It resulted in a $5,362 investment by the insider. Hagan Joseph P added 100,000 shares at an average price of $0.22 on Jan 26. The insider now owns 417,006 shares following the transaction. On May 17, President and CEO Hagan Joseph P sold 4,186 shares at $0.89 apiece. The transaction was valued at $3,726.

Valuation Metrics

The stock’s beta is 2.21. Besides these, the trailing price-to-sales (P/S) ratio of 6.41, the price-to-book (PB) ratio of 0.42.

Financial Health

In the three months ended September 29, Regulus Therapeutics Inc.’s quick ratio stood at 12.50, while its current ratio was 12.50, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending September 29 was 0.09, and the total debt-to-equity ratio was 0.09. Based on annual data, RGLS earned $27.82 million in gross profit.

While analysts expected Regulus Therapeutics Inc. to report -$0.08 quarterly earnings, the actual figure was -$0.1 per share, beating the consensus estimate by -25.00%. During the quarter, the company generated -$6.92 million in EBITDA. The liabilities of Regulus Therapeutics Inc. were 13.5 million at the end of its most recent quarter ended September 29, and its total debt was $9.11 million. The value of shareholders’ equity is $145.97 million.

Technical Picture

This quick technical analysis looks at Regulus Therapeutics Inc.’s (RGLS) price momentum. With a historical volatility rate of 254.08%, the RSI 9-day stood at 50.37% on 13 May.

With respect to its five-day moving average, the current Regulus Therapeutics Inc. price is up by +25.17% percent or $0.0433. At present, RGLS shares trade -15.40% below its 20-day simple moving average and -35.96% percent below its 100-day simple moving average. However, the stock is currently trading approximately -25.48% below its SMA50 and -69.82% below its SMA200.

Stochastic coefficient K was 50.60% and Stochastic coefficient D was 40.78%, while ATR was 0.0451. Given the Stochastic reading of 34.47% for the 14-day period, the RSI (14) reading has been calculated as 48.13%. As of today, the MACD Oscillator reading stands at 0.0445, while the 14-day reading stands at 0.0415.

Analyst Ratings

B. Riley FBR Inc. launched its rating on Regulus Therapeutics Inc. (NASDAQ: RGLS) to a Neutral in a note to investors on March 28, 2018. Regulus Therapeutics Inc. (RGLS) has been rated Overweight by analysts. According to 0 brokerage firms, RGLS is a sell, and 1 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Regulus Therapeutics Inc. stock as buy, with 2 recommending it as overweight.

With a median target price of $2.00, the current consensus forecast for the stock is $0.50 – $2.00. Based on these forecasts, analysts predict Regulus Therapeutics Inc. (RGLS) will achieve an average price target of $1.50.


Please enter your comment!
Please enter your name here

Hot Topics

Related Articles